In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Alkermes (ALKS), with a price target of $34. The company’s shares closed last Monday at $22.62, close to its 52-week low of $19.36.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 6.2% and a 41.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alkermes with a $26.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $45.16 and a one-year low of $19.36. Currently, Alkermes has an average volume of 1.32M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
